Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SYRE 
Spyre Therapeutics Inc. (SYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: SYRE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $52.91
1 Year Target Price $52.91
| 10 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.58% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.90B USD | Price to earnings Ratio - | 1Y Target Price 52.91 |
Price to earnings Ratio - | 1Y Target Price 52.91 | ||
Volume (30-day avg) 11 | Beta 2.91 | 52 Weeks Range 10.91 - 40.26 | Updated Date 11/2/2025 |
52 Weeks Range 10.91 - 40.26 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.7736 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.48% | Return on Equity (TTM) -49.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 810857340 | Price to Sales(TTM) 650.22 |
Enterprise Value 810857340 | Price to Sales(TTM) 650.22 | ||
Enterprise Value to Revenue 1964.91 | Enterprise Value to EBITDA -7.96 | Shares Outstanding 77495554 | Shares Floating 52572996 |
Shares Outstanding 77495554 | Shares Floating 52572996 | ||
Percent Insiders 6.79 | Percent Institutions 83.38 |
Upturn AI SWOT
Spyre Therapeutics Inc.
Company Overview
History and Background
Spyre Therapeutics Inc. was founded in 2022 and is focused on developing novel therapeutics for inflammatory bowel disease (IBD). They aim to improve outcomes for patients by developing next-generation precision medicines.
Core Business Areas
- Drug Development: Focuses on creating novel antibody therapeutics for IBD, targeting specific disease pathways.
Leadership and Structure
Cameron Turtle is the CEO. The organizational structure is typical for a biotech company, with research, development, clinical, and administrative functions.
Top Products and Market Share
Key Offerings
- SPY001: A humanized anti-TL1A antibody in Phase 1 trials targeting inflammatory bowel disease (IBD). Competitors include Prometheus Biosciences (acquired by Merck), Roivant Sciences, and other companies developing TL1A inhibitors. Market share is currently zero as the product is still in development.
- SPY002: A humanized anti-alpha 4 beta 7 antibody (integrin antagonist) for IBD. Competitors include Takeda's Entyvio. Market share is currently zero as the product is still in development.
- SPY003: Engineered cytokine therapeutic candidate for IBD.
Market Dynamics
Industry Overview
The IBD therapeutics market is substantial and growing, driven by increasing prevalence, unmet medical needs, and the availability of new biologics and small molecules. Competition is fierce, with established players and emerging biotech companies vying for market share.
Positioning
Spyre is positioned as an innovative biotech company focused on developing next-generation IBD therapies with potentially improved efficacy and safety profiles compared to existing treatments. Their competitive advantage lies in their targeted approach and novel antibody engineering.
Total Addressable Market (TAM)
The global IBD market is estimated to be worth over $20 billion. Spyre's positioning aims to capture a significant share of this TAM by addressing unmet needs in IBD treatment.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidates
- Experienced management team
- Focus on precision medicine
- Strong intellectual property portfolio
Weaknesses
- Early-stage clinical development
- Limited financial resources compared to larger competitors
- Reliance on clinical trial success
- High attrition rate in drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new IBD subtypes
- Acquisition by a larger company
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- TAK
- BMY
Competitive Landscape
Spyre faces competition from established pharmaceutical companies with existing IBD therapies and other biotech companies developing novel treatments. Their success will depend on demonstrating superior efficacy and safety in clinical trials.
Major Acquisitions
Perseus BioPharmaceuticals, Inc
- Year: 2023
- Acquisition Price (USD millions): 0
- Strategic Rationale: Spyre acquired Perseus to bolster its pipeline with an anti-TL1A antibody.
Growth Trajectory and Initiatives
Historical Growth: Not applicable, as Spyre Therapeutics Inc. is a recently founded company.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates are available but subject to significant uncertainty.
Recent Initiatives: Focus on advancing SPY001 and SPY002 through clinical trials.
Summary
Spyre Therapeutics is a very early-stage biotech company focused on IBD. The company has promising therapeutic candidates, but faces significant risks typical of biotech companies, including clinical trial failures and competition. Success hinges on achieving positive clinical trial results and securing partnerships or acquisitions. Their acquisitions and focus on precision medicine provides a strength.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spyre Therapeutics Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2016-04-07 | CEO & Director Dr. Cameron Turtle DPHIL, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 87 | Website https://www.spyre.com |
Full time employees 87 | Website https://www.spyre.com | ||
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.